High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery

Neurocritical Care

Volumn 16, Issue 2, 2012, Pages 267-272

  Li, Qiang ^a   Yao, Gaiqi ^a   Zhu, Xi ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Ambroxol; Cervical spinal cord injury; Pulmonary complications

Indexed keywords

AMBROXOL; CEFMINOX; PIPERACILLIN; SULBACTAM;

ARTERIAL GAS; ARTICLE; ATELECTASIS; BLOOD GAS ANALYSIS; CERVICAL SPINAL CORD INJURY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HYPOXEMIA; HYPOXIA; INTENSIVE CARE UNIT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; OXYGENATION; PATIENT CODING; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE;

AGED; AMBROXOL; ANOXIA; CERVICAL VERTEBRAE; EXPECTORANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PNEUMONIA; POSTOPERATIVE COMPLICATIONS; PULMONARY ATELECTASIS; SPINAL CORD INJURIES;

EID: 84860881924     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9642-4     Document Type: Article

References (37)

1. Romanini BM, Sandri MG, Tosi M, Mezzetti M, Mazzetti A. Ambroxol for prophylaxis and treatment of bronchopulmonary complications after chest surgery. Int J Clin Pharmacol Res. 1986;6:123-7. (Pubitemid 16004486)
2. Fegiz G. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: double-blind Italian multicenter clinical study versus placebo. Lung. 1991;169:69-76.
3. Refai M, Brunelli A, Xiumé F, Salati M, Sciarra V, Socci L, et al. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial. Eur J Cardiothorac Surg. 2009; 35:469-73.
4. Ulas MM, Hizarci M, Kunt A, Ergun K, Kocabeyoglu SS, Korkmaz K, et al. Protective effect of Ambroxol on pulmonary function after cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008;52(6):518-23.
5. Marino RJ, Barros T, Biering-Sorensen F, Burns SP, Donovan WH, Graves DE. International standards for neurological classification of spinal cord injury. J Spinal Cord Med. 2003; 26(Suppl 1):S50-6.
6. Velmahos GC, Toutouzas K, Chan L, Tillou A, Rhee P, Murray J, et al. Intubation after cervical spinal cord injury: to be done selectively or routinely? Am Surg. 2003;69:891-4.
7. DeVivo MJ, Stover SL. Long-term survival and causes of death. In: Stover SL, Dehisa JA, Whiteneck G, editors. Spinal Cord Injury: Clinical Outcomes from the Model Systems. Gaithers-burg: Aspen; 1995. p. 289-316.
8. Carter RE. Unilateral diaphragmatic paralysis in spinal cord injury patients. Paraplegia. 1980;28:267-73. (Pubitemid 10036808)
9. Axen K, Pineda H, Shunfenthal I, Haas F. Diaphragmatic function following cervical cord injury: neurally mediated improvement. Arch Phys Med Rehabil. 1985;66:219-22. (Pubitemid 15096493)
10. Tremblay LN, Slutsky AS. Ventilator-induced injury: from bar-otrauma to biotrauma. Proc Assoc Am Physicians. 1988;110: 482-8.
11. Vreugdenhil HA, Heijnen CJ, Plötz FB, Zijlstra J, Jansen NJ, Haitsma JJ, Lachmann B, van Vught AJ. Mechanical ventilation of healthy rats suppresses peripheral immune function. Eur Respir J. 2004;23:122-8. (Pubitemid 38088508)
12. Ericsson CH, Juhász J, Mossberg B, Philipson K, Svartengren M, Camner P. Activation of human macrophages by mechanical ventilation in vitro. Am J Physiol. 1998;275(6 Pt 1):L1040-50.
13. Vlahakis NE, Schroeder MA, Limper AH, Hubmayr RD. Stretch induces cytokine release by alveolar epithelia cells in vitro. Am J Physiol. 1999;277(1 Pt 1):L167-73. (Pubitemid 29356764)
14. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest. 1997; 99:944-52. (Pubitemid 27123631)
15. Wrigge H, Uhlig U, Baumgarten G, Menzenbach J, Zinserling J, Ernst M, Dromann D. Mechanical ventilation strategies and inflammatory responses to cardiac surgery: a prospective randomized clinical trial. Intensive Care Med. 2005;31:1379-87. (Pubitemid 41437731)
16. Michelet P, D'Journo XB, Roch A, Doddoli C, Marin V, Pa-pazian L, et al. Protective ventilation influences systemic inflammation after esophagectomy: a randomized controlled study. Anesthesiology. 2006;105:911-9. (Pubitemid 44655501)
17. Wolthuis EK, Choi G, Dessing MC, Bresser P, Lutter R, Dzoljic M. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents pulmonary inflammation in patients without preexisting lung injury. Anesthesiology. 2008; 108:46-54.
18. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Anc-ukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33:1-6. (Pubitemid 40116529)
19. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med. 2004;32:1817-24. (Pubitemid 39202355)
20. Wolthuis EK, Choi G, Dessing MC, Bresser P, Lutter R, Dzoljic M, et al. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents pulmonary inflammation in patients without preexisting lung injury. Anesthesiology. 2008;108:46-54.
21. Determann RM, Wolthuis EK, Choi G, Bresser P, Bernard A, Lutter R, et al. Lung epithelial injury markers are not influenced by use of lower tidal volumes during elective surgery in patients without preexisting lung injury. Am J Physiol. 2008;294: L344-50. (Pubitemid 351253371)
22. Schultz MJ, Haitsma JJ, Slutsky AS, Gajic O. What tidal volumes should be used in patients without acute lung injury? Anesthe-siology. 2007;106:1226-31. (Pubitemid 46828177)
23. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A. Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med. 2005;31:922-6. (Pubitemid 40941723)
24. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med. 2004;32:1817-24. (Pubitemid 39202355)
25. Pfeifer S, Zissel G, Kienast K, Muller-Quernheim J. Reduction of cytokine release from blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res. 1997;2:129-32.
26. Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff HH, et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res. 1999;48:86-93. (Pubitemid 29110236)
27. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008;13:557-62.
28. Su X, Wang L, Song Y, Bai C. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004;30:133-40. [Epub 2003 Sep 20]. (Pubitemid 38147119)
29. Paganin F, Bouvet O, Chanez P, Fabre D, Galtier M, Godard P, et al. Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Biopharm Drug Dispos. 1995;16:393-401.
30. Derelle J, Bertolo-Houriez E, Marchal F, Weber M, Virion JM, Vidailhet M. Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus domase alfa. Arch-Pediatr. 1998;5:371-7. (Pubitemid 28176274)
31. Gené R, Poderoso JJ, Corazza C, Lasala MB, Wiemeyer JC, Fernández M, et al. Influence of ambroxol on amoxicillin levels in bronchoalveolar lavage fluid. Arzneimittelforschung. 1987;37: 967-8.
32. Spátola J, Poderoso JJ, Wiemeyer JC, Fernández M, Guerreiro RB, Corazza C. Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneimittelforschung. 1987;37:965-6.
33. Wiemeyer JC. Influence of ambroxol on the bronchopulmonary level of antibiotics. Arzneimittelforschung. 1981;31:974-6. (Pubitemid 11117100)
34. Li F, Wang W, Hu L, Li L, Yu J. Effect of Ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy. 2011;57:173-80. [Epub 2011 April 1].
35. Lu Q, Yu J, Yang X, Wang J, Wang L, Lin Y, et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int J Antimicrob Agents. 2010;36:211-5. [Epub 2010 Jun 26].
36. Hafez MM, Aboulwafa MM, Yassien MA, Hassouna NA. Activity of some mucolytics against bacterial adherence to mammalian cells. Appl Biochem Biotechnol. 2009;158:97-112. Epub 2008 Aug 12.
37. Xie DS, Xiong W, Lai RP, Liu L, Gan XM, Wang XH, et al. Ventilator-associated pneumonia in intensive care units in Hubei Province, China: a multicentre prospective cohort survey. J Hosp Infect. 2011;78:284-8. [Epub 2011 April 20].